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Infectious Complications of Pediatric Liver Transplantation 
Under FK 506 
M. Green. A. Tzakis, J. Reyes. 8. Nour. S. Todo. and T.E. Starzl 
THE introduction of cyclosponne (CyA) has been as-
sociated with the evolution of liver transplantation as 
an effective therapy for children with end-stage liver 
disease. However. long-term toxicity of CyA and failures 
due to chronic rejection have prompted evaluation of the 
new immunosuppressant. FK 506. in pediatric liver trans-
plant recipients at the Children' s Hospital of Pittsburgh. 
The pu~se of the following case-control study was to 
compare the infectious complications seen in patients 
treated with FK 506 to randomly assigned recent historical 
controls treated with conventional immunosuppression. 
METHODS 
Beginning In October 1989. children undergoing first-lime ortho-
tOPIC liver transplantation IOLT) were eligible to participate In a 
histoncallv controlled. clanical evaluation of the new immunosup-
pressant. FK 506. A sangle control was randomly selected from a 
set of matched candidate controls for each pallent treated with FK 
506. Matching was performed for age (within 6 months). primary 
diagnOSIS. and "UNOS" seventy score as soon as poSSible after 
the transplant. Inpatient and outpatient chans were systematically 
reViewed ulilizing standardized datasheets and definitions I 10 
compare 9O-day outcome. Datapoants from the inpatient chart 
review included patient outcome. immunosuppressive therapy. 
episodes of rejection. and episodes of infection. 
Maintenance immunosuppressive management. as well as the 
treatment of rejection In the two groups of patients was as 
prevlOuslv descnbed. ".J 
Proportions were analvzed with the chi-square test. and means 
were compared with the Student's I test. 
RESULTS 
Sixty-one children were treated with FK 506 as their 
primarY Immunosuppressant between October 1989 and 
October 1990. Fifty-one controls were identified for these 
patients. No control was Identified for 10 patients because 
of either an unusual diagnOSIs or a common diagnosis 
presenting for transplant at an unusual age. However. for 
the purpose of this analvsls. these unmatched patients 
were meluded in the FK 506 group. 
Congenital diseases. including biliary atresia and neona-
tal hepatitis. were the most common diagnoses 10 both 
groups. The mean age of the FK 506 group was 4,4 years 
compared to 3.4 years 10 control patients IP :: NS1. This 
difference 10 age IS accounted for by the 10 unmatched 
patients who tended to be older I mean = 8.7 yearsl. Six of 
the 61 pallents treated wllh FK 506 died in the first 90 days 
posnransplant compared to 13 of 51 control patients I P = 
06) Two io the deaths In control pallents occurred during 
the pnmary transplant procedure. Six of 61 children 
treated with FK 506 required retransplantation compared 
to 10 of 51 control patients (P = NS). 
An overview of the infectious complications seen in 
both treatment groups is shown in Table I. The mean 
number of infectious episodes was significantly less in 
patients treated with FK S06 compared to controls (1.2 vs 
1.8. P < .05). The type and timing of infection were similar 
in the two groups. 
The mean onset of bactenal infection was 23 days after 
the transplant. and was not different between the two 
groups. The most common infection in each group was 
bacteremia (Table 1 l. and the most common pathogens 
were gram-positive organisms. The major difference be-
tween the two groups of patients was the frequency of 
Table 1. Overvtew of Inftlctlou. Complication. During the Firat 
90 0 • .,. Aft., Pediatric OLT 
FK508 CanIraI 
No. patients 61 51 
Infectious epiSOdes 78 98 
EpiSOdeS/palient 1.2 18· 
Fatal Infections 2 r 
Blldenal 38 55 
Bacteremia 13 32 
Une-asaoc1ated 5 19 
Other source identified 4 10 
Intra·abdomlnal (nonbacteremlc) 5 8 
Ententls 4 4 
Wouno 4 2 
Pneumonia InonbacteremlCl 3 3 
Otitis medla'SlnuSltIS 8 4 
U nnary tract 2 4 
Viral infectIOns 30 33 
CytomegaloVIrus 12 13 
InvUlve 9 9 
AdenoviruS 4 7 
Invulve 0 5 
EBV'PTLO 1 1 
Fungal Infections 7 6 
Mixed infection' 3 2 
. p < 05. r p. 08: 'n"xeQ llaC:I8tIal ana fungal anledIOn. 
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INFECTIOUS COMPLICATIONS 
catheter-associated bacteremia. and is explained by a 
change In our usage of central venous catheters_ After 
exclusion of catheter-associated bacteremias. the differ-
ence in the mean number of infections is no longer signif-
icant. 
The overall incidence of viral infection was similar in the 
two groups (Table I). The mean onset of viral infection 
was 33 days after transplantation and was not different 10 
either treatment group. CMV was the most common 
pathogen. and caused invasive disease in the majority of 
episodes in both groups. AdenOVirus was the next most 
common pathogen: invasive disease appeared to be more 
common in controls. 
Isolated fungal infections were noted in seven of the 
children treated with FK 506 compared to six control 
patients. Mixed infections. consisting of Candida species 
and bacteria. were additionally noted in three FK 506 and 
two control patients. Infection due to Aspt'rgil/us /umiga-
/IIS contnbuted to the death of one and caused pneumonia 
in another child with cystic fibrosis transpla.nted under FK 
506. The remaining fungal infections were due to Candida 
species. Despite the fact that five episodes of invasive 
candidiaSIS were noted in both treatment groups. the only 
death due to fungal disease identified during the study 
period was the previously mentioned child who had con-
current asperillosis of his hean and disseminated candidi-
asis <Table 2). 
Pathogens and clinical syndromes associated with infec-
tious deaths are shown in Table 2. A trend toward an 
increase in fatal infections was observed in the control 
group 12 of 61 vs 7 of 51. P =08). Severe pneumonitis. 
associated with adult respiratory distress syndrome. was 
the most common fatal infectious syndrome observed in 
this study. 
DISCUSSION 
This study suggests that the type. timing. and frequency of 
infections seen after liver transplantation are similar in 
children receiving FK 506 as immunosuppression com-
pared to recent historical controls treated with conven-
tional immunosuppression. The decreased rate of bactenal 
mfectlons among patients treated with FK 506 is likely 
explained by a dramatic reduction in our current use of 
central venous catheters. which preceded the onset of this 
clinical tnaL 
3039 
Table 2. InhK:tloua DMtha Arter Pedlatrtc OLTx 
Immunosuooressaon PaltlOgen Clinical SyndrOme 
FK506 Aspergttius Carclltls 
Candida Disseminated disease 
FK 506 CMV Pneumonla'ARDS 
Control S.aUI8fJS Septic shOCk. 
Control £. cloacae SepbC ShOCK 
Control E. cloacae Pneumonia ARDS 
Control Adenovirus Pneumonia ARDS 
Controt Adenovirus Pneumonia ARDS 
CMV 
Control CMV Pneumonia ARDS 
Control Influenza A PneumonlaARDS 
A trend toward an increase in fatal infections was 
observed in the control group in this study suggesting that 
patients transplanted under FK 506 may experience less 
infection-associated mortality than those treated with tra-
ditional immunosuppressive regimens. Although limited 
by the small number of patients observed in thIS study. the 
trend appeared to hold for both bacterial and mal infec-
tions. This observation may be explained by a decreased 
use of conicosteroids and OKT3 in the children treated 
with FK 506. 4 
Evaluation of the first 3 months after pediatric liver 
transplant demonstrates no increase. and perhaps. a de-
crease in infectious disease morbidity and mortality in 
pediatric liver transplant recipients treated with FK 506. 
These findings. along with a trend toward increased sur-
vival and the previously reponed benefits of less steroid 
and anllhypenensive requirement in these chIldren. sug-
gests (hat FK 506 is superior to conventional immunosup-
pression. Conllnued follow-up for late mfectlous sequelae, 
including the development of posttransplant I"mphoprolif-
c:ratlve disease. are necessary to complete these observa-
tions. 
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